AEON

Investor Moves

Investor	Portfolio Value	Portfolio Change	Position Change	Avg Buy Price	Current Price
Ken GriffinCitadel Advisors $-12.8K ExitQ1 2026 $13k -- $0.7586

News

globenewswire.comAEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Societyglobenewswire.comJun 4

globenewswire.comAEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Updateglobenewswire.comMay 14

globenewswire.comAEON Biopharma Sets Annual Shareholder Meetingglobenewswire.comApr 24

defenseworld.netAerovate Therapeutics (NASDAQ:AVTE) & AEON Biopharma (NASDAQ:AEON) Head to Head Surveydefenseworld.netApr 13

Trade AEON

About AEON Biopharma, Inc.

AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum toxin complex, which is being advanced for therapeutic use in conditions such as migraine, cervical dystonia, and gastroparesis. The entity, originally known as ALPHAEON Corporation, adopted the name AEON Biopharma, Inc. in December 2019. Established in 2012, the company maintains its principal operations from Newport Beach, California.

CEO: Robert Bancroft
IPO Date: Jul 24, 2023

Market Data

Open: $0.7367
High: $0.7367
Low: $0.6812
Volume: 54.4K
52W High: $1.45
52W Low: $0.625

Valuation

Market Cap: $8.4M
Enterprise Value: $4.8M

Financials

Free Cash Flow: $-17M
Revenue: $0
Net Income: $-39M
Cash: $3.0M
Debt: $36M

Events

EarningsAug 11

EPS est. -0.33